Therefore, promoting HO‐1 expression could be a potential therapeutic target for treating osteoporosis.[29] Our research suggests that DFO‐loaded PDAP NPs can enhance HO‐1 expression while suppressing osteoclast‐related gene expression such as Acp5, Nfatc1, and Ctsk, as well as osteoclast activity. The gene discussed is CTSK; the disease is osteoporosis.